FDA Approves First Automated Insulin Delivery Device for Type 1 Diabetes. September28, 2016. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm522974.htm (accessed September28, 2016).
KovatchevB, ChengP, AndersonSM, et al.Feasibility of long-term closed-loop control: a multicenter 6-Month Trial of 24/7 automated insulin delivery. Diabetes Technol Ther, 2017; 19:18–24.
4.
GargSK, WeinzimerSA, TamborlaneWV, et al.Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther, 2017; 19:155–163.
5.
BergenstalRM, GargS, WeinzimerSA, et al.Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA, 2016; 316:1407–1408.
6.
SpaicT, DriscollM, RaghinaruD, et al.Predictive hyperglycemia and hypoglycemia minimization: in-home evaluation of safety, feasibility, and efficacy in overnight glucose control in type 1 diabetes. Diabetes Care, 2017; 40:359–366.
7.
WangY, ZhangJ, ZengF, et al.“Learning” can improve the blood glucose control performance for type 1 diabetes mellitus. Diabetes Technol Ther, 2017; 19:41–48.
8.
TalebN, EmamiA, SuppereC, et al.Efficacy of single-hormone and dual-hormone artificial pancreas during continuous and interval exercise in adult patients with type 1 diabetes: randomised controlled crossover trial. Diabetologia, 2016; 59:2561–2571.
9.
RussellSJ, HillardMA, BalliroC, et al.Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial. Lancet Diabetes Endocrinol, 2016; 4:233–243.
10.
JacobsPG, El YoussefJ, ReddyR, et al.Randomized trial of a dual-hormone artificial pancreas with dosing adjustment during exercise compared with no adjustment and sensor-augmented pump therapy. Diabetes Obes Metab, 2016; 18:1110–1119.
11.
DeBoerMD, ChernavvskyDR, TopchyanK, et al.Heart rate informed artificial pancreas system enhances glycemic control during exercise in adolescents with T1D. Pediatr Diabetes, 2016; PMID: 27734563; doi: 10.1111/pedi.12454.
12.
CameronF, NiemeyerG, WilsonDM, et al.Inpatient trial of an artificial pancreas based on multiple model probabilistic predictive control with repeated large unannounced meals. Diabetes Technol Ther, 2014; 16:728–734.
13.
BretonMD, BrownSA, KarvetskiCH, et al.Adding heart rate signal to a control-to-range artificial pancreas system improves the protection against hypoglycemia during exercise in type 1 diabetes. Diabetes Technol Ther, 2014; 16:506–511.
14.
WardWK, HeinrichG, BreenM, et al.An amperometric glucose sensor integrated into an insulin delivery cannula: in vitro and in vivo evaluation. Diabetes Technol Ther, 2017; 19:226–236.
15.
RodriguezLT, FriedmanKA, CoffmanSS, HellerA. Effect of the sensor site-insulin injection site distance on the dynamics of local glycemia in the minipig model. Diabetes Technol Ther, 2011; 13:489–493.
16.
LindpointnerS, KorsatkoS, KohlerG, et al.Glucose levels at the site of subcutaneous insulin administration and their relationship to plasma levels. Diabetes Care, 2010; 33:833–838.
17.
RumplerM, MaderJK, FischerJP, et al.First application of a transcutaneous optical single-port glucose monitoring device in patients with type 1 diabetes mellitus. Biosens Bioelectron, 2017; 88:240–248.
ClarkeWL. The original Clarke Error Grid Analysis (EGA). Diabetes Technol Ther, 2005; 7:776–779.
20.
NorgaardK, ShinJ, WelshJB, GjessingH. Performance and acceptability of a combined device for insulin infusion and glucose sensing in the home setting. J Diabetes Sci Technol, 2015; 9:215–220.
21.
DamianoER, McKeonK, El-KhatibFH, et al.A comparative effectiveness analysis of three continuous glucose monitors: the Navigator, G4 Platinum, and Enlite. J Diabetes Sci Technol, 2014; 8:699–708.
22.
MatulevicieneV, JosephJI, AndelinM, et al.A clinical trial of the accuracy and treatment experience of the Dexcom G4 sensor (Dexcom G4 system) and Enlite sensor (guardian REAL-time system) tested simultaneously in ambulatory patients with type 1 diabetes. Diabetes Technol Ther, 2014; 16:759–767.
23.
KarlinAW, LyTT, PyleL, et al.Duration of infusion set survival in lipohypertrophy versus nonlipohypertrophied tissue in patients with type 1 diabetes. Diabetes Technol Ther, 2016; 18:429–435.
24.
PatelPJ, BenasiK, FerrariG, et al.Randomized trial of infusion set function: steel versus teflon. Diabetes Technol Ther, 2014; 16:15–19.
25.
RossPL, MilburnJ, ReithDM, et al.Clinical review: insulin pump-associated adverse events in adults and children. Acta Diabetol, 2015; 52:1017–1024.
26.
GibneyM, XueZ, SwinneyM, et al.Reduced silent occlusions with a novel catheter infusion set (BD FlowSmart): results from two open-label comparative studies. Diabetes Technol Ther, 2016; 18:136–143.
27.
BequetteBW. Fault detection and safety in closed-loop artificial pancreas systems. J Diabetes Sci Technol, 2014; 8:1204–1214.
28.
HowsmonDP, CameronF, BaysalN, et al.Continuous glucose monitoring enables the detection of Losses in Infusion Set Actuation (LISAs). Sensors (Basel), 2017; 17: pii: E161.
